PKA Inhibitor Fragment (6-22) amide (TFA)

CC[C@H](C)[C@@H](C(N)=O)NC([C@H](C)NC([C@H](CC(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC(CNC([C@H]([C@H](O)C)NC([C@H](CCCNC(N)=N)NC(CNC([C@H](CO)NC([C@H](C)NC([C@H]([C@@H](C)CC)NC([C@@H](NC([C@H](CC(O)=O)NC([C@H](C)NC([C@@H](NC([C@@H](N)[C@H](O)C)=O)CC1=CC=C(C=C1)O)=O)=O)=O)CC2=CC=CC=C2)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O.[x]

[1]Katz BM, et, al. Synthesis, characterization and inhibitory activities of (4-N3[3,5-3H]Phe10) PKI (6-22) amide and its precursors: photoaffinity labeling peptides for the active site of cyclic AMP-dependent protein kinase. Int J Pept Protein Res. 1989 Jun;33 (6) :439-45.|[2]Dalton GD, et, al. Alterations in brain Protein Kinase A activity and reversal of morphine tolerance by two fragments of native Protein Kinase A inhibitor peptide (PKI) . Neuropharmacology. 2005 Apr; 48 (5) : 648-57.